LEADER 04862nam 2200661Ia 450 001 9910133641603321 005 20170810182527.0 010 $a1-283-83537-1 010 $a3-527-63389-8 010 $a3-527-63388-X 035 $a(CKB)3400000000000401 035 $a(EBL)661793 035 $a(OCoLC)768731436 035 $a(SSID)ssj0000507243 035 $a(PQKBManifestationID)11303294 035 $a(PQKBTitleCode)TC0000507243 035 $a(PQKBWorkID)10545717 035 $a(PQKB)11256023 035 $a(MiAaPQ)EBC661793 035 $a(EXLCZ)993400000000000401 100 $a20110808d2011 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aApicomplexan parasites$b[electronic resource] $emolecular approaches toward targeted drug development /$fedited by Katja Becker 205 $a4th ed. 210 $aWeinheim $cWiley-Blackwell$dc2011 215 $a1 online resource (552 p.) 225 1 $aDrug discovery in infectious diseases ;$vv. 2 300 $aDescription based upon print version of record. 311 $a3-527-32731-2 320 $aIncludes bibliographical references and index. 327 $aApicomplexan Parasites: Molecular Approaches toward Targeted Drug Development; Foreword; Contents; Preface; List of Contributors; Part One: Screening, Bioinformatics, Chemoinformatics, and Drug Design; 1 Drug Discovery Approaches Toward Anti-Parasitic Agents; 2 New Bioinformatic Strategies Against Apicomplexan Parasites; 3 Sorting Potential Therapeutic Targets in Apicomplexa; 4 Alternatives to Drug Development in the Apicomplexa; Part Two: Metabolic Pathways and Processes Addressed by Current Drug Discovery Approaches; 5 Energy Metabolism as an Antimalarial Drug Target 327 $a6 Polyamines in Apicomplexan Parasites7 The Reducing Milieu of Parasitized Cells as a Target of Antimalarial Agents: Methylene Blue as an Ethical Drug; 8 Lipids as Drug Targets for Malaria Therapy; 9 Targeting Apicoplast Pathways in Plasmodium; 10 Lipoic Acid Acquisition and Glutathione Biosynthesis in Apicomplexan Parasites; 11 Antimalarial Drugs and Molecules Inhibiting Hemozoin Formation; 12 Exploiting the Vitamin Metabolism of Apicomplexa as Drug Targets; 13 Vitamin Biosynthetic Pathways, the PLP Synthase Complex, and the Potential for Targeting Protein-Protein Interaction 327 $a14 Targeting Prokaryotic Enzymes in the Eukaryotic Pathogen CryptosporidiumPart Three: Drug Targets in Apicomplexan Parasites; 15 Novel Apicomplexan Phosphatases and Immunophilins as Domain-Specific Drug Targets; 16 Dehydrogenases and Enzymes of the Mitochondrial Electron Transport Chain as Anti-Apicomplexan Drug Targets; 17 Calcium-Dependent Protein Kinases as Drug Targets in Apicomplexan Parasites; 18 Protein Acylation: New Potential Targets for Intervention Against the Apicomplexa; 19 Drugs and Drug Targets in Neospora caninum and Related Apicomplexans; Part Four: Compounds 327 $a20 Subversive Substrates of Glutathione Reductases from Plasmodium falciparum-Infected Red Blood Cells as Antimalarial Agents21 Ferroquine: A Concealed Weapon; 22 Current Aspects of Endoperoxides in Antiparasitic Chemotherapy; 23 Plasmodium Hsp90 as an Antimalarial Target; 24 Drug Discovery Against Babesia and Toxoplasma; 25 Search for Drugs and Drug Targets against Babesia bovis, Babesia bigemina, Babesia caballi, and Babesia (Theileria) equi; 26 Orlistat: A Repositioning Opportunity as a Growth Inhibitor of Apicomplexan Parasites?; 27 Recent Drug Discovery Against Cryptosporidium; Index 330 $aThis handbook is the first dealing with the discovery of drugs directed against apicomplexan parasites. Amongst others, this group of endoparasites includes the causative agents of Malaria, Toxoplasmosis, and Babesiosis, the latter occurring mainly in animals. Written by renowned scientific experts from academia and industry, the book focuses on currentdrug development approaches for all apicomplexan diseases making it appealing to a large audience, ranging from research labs in academia to the human and veterinarian pharmaceutical industry. This work is the second volume of the new book seri 410 0$aDrug discovery in infectious diseases ;$vv. 2. 606 $aAntiprotozoal agents 606 $aProtozoan diseases$xChemotherapy 606 $aApicomplexa 606 $aDrug development 608 $aElectronic books. 615 0$aAntiprotozoal agents. 615 0$aProtozoan diseases$xChemotherapy. 615 0$aApicomplexa. 615 0$aDrug development. 676 $a616.9/6 701 $aBecker$b Katja$f1965-$0988621 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910133641603321 996 $aApicomplexan parasites$92260616 997 $aUNINA LEADER 03348oam 2200625I 450 001 9910970548103321 005 20251116162430.0 010 $a0-429-91998-0 010 $a0-367-32742-2 010 $a0-429-90575-0 010 $a0-429-48098-9 024 7 $a10.4324/9780429480980 035 $a(CKB)2670000000616726 035 $a(EBL)2052178 035 $a(SSID)ssj0001546276 035 $a(PQKBManifestationID)16134631 035 $a(PQKBTitleCode)TC0001546276 035 $a(PQKBWorkID)14792168 035 $a(PQKB)11051282 035 $a(Au-PeEL)EBL2052178 035 $a(CaPaEBR)ebr11057293 035 $a(CaONFJC)MIL785412 035 $a(OCoLC)909857193 035 $a(OCoLC)1029482330 035 $a(MiAaPQ)EBC2052178 035 $a(EXLCZ)992670000000616726 100 $a20180706d2018 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 14$aThe Abandonment Neurosis /$fGermaine Guex ; translated by Peter D. Douglas 205 $aFirst edition. 210 1$aLondon :$cTaylor and Francis,$d2018. 215 $a1 online resource (150 p.) 225 1 $aHistory of Psychoanalysis Series 300 $aDescription based upon print version of record. 311 08$a1-78220-191-2 311 08$a1-78241-326-X 320 $aIncludes bibliographical references and index. 327 $aCOVER; CONTENTS; ACKNOWLEDGEMENTS; ABOUT THE AUTHOR; ABOUT THE TRANSLATOR; TRANSLATOR'S PREFACE; SERIES EDITOR'S FOREWORD; Introduction; CHAPTER ONE Clinical description of symptomatology; CHAPTER TWO Structures; CHAPTER THREE Aetiology; CHAPTER FOUR Therapy; NOTES; REFERENCES; INDEX 330 $a"First published in 1950, La nevrose d'abandon was and still is a ground-breaking work. Guex's research turns on two clinical observations: the frequent occurrence of analysands whose neurotic symptoms are unrecognizable when measured against any of the Freudian diagnostic models, and the relatively large number of these patients who sought help from her, having already undergone thorough classically Freudian treatments with analysts whose abilities were never in question, but whose efforts did nothing to relieve patient suffering.What all these subjects had in common, Guex observed, were extme and debilitating feelings of abandonment, insecurity and lack of self-worth, originally ignited by severe pre-oedipal trauma. Having described the neurosis of abandonment, Guex goes on to outline every diagnostic tool and treatment methodology, developed over many years, which can be deployed in the successful and lasting eradication of this pervasive neurosis.Despite its trail-blazing research and ideas, Guex's book never received the accolades or attention it deserved. Now, translated into English for the first time by Peter D. Douglas, it is brought to a new and wider audience, for whom the ideas it explores are just as relevant and significant today."--Provided by publisher. 410 0$aHistory of psychoanalysis series. 606 $aNeuroses 615 0$aNeuroses. 676 $a616.852 700 $aGuex$b Germaine$0254655 702 $aDouglas$b Peter D. 801 0$bFlBoTFG 801 1$bFlBoTFG 906 $aBOOK 912 $a9910970548103321 996 $aThe Abandonment Neurosis$94487908 997 $aUNINA